selegiline has been researched along with Central Nervous System Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boulton, AA; Juorio, AV; Li, XM; Paterson, IA | 1 |
| Factor, S; Hubble, J; Kurlan, R; Richard, IH; Suchowersky, O; Tanner, C; Waters, C | 1 |
| Delanty, N; Praticò, D | 1 |
1 review(s) available for selegiline and Central Nervous System Diseases
| Article | Year |
|---|---|
Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Antioxidants; Ascorbic Acid; Benzoquinones; Central Nervous System; Central Nervous System Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Free Radicals; Ginkgo biloba; Humans; Lipid Peroxidation; Neuroprotective Agents; Oxidation-Reduction; Phytotherapy; Plants, Medicinal; Selegiline; Ubiquinone; Vitamin E | 2000 |
2 other study(ies) available for selegiline and Central Nervous System Diseases
| Article | Year |
|---|---|
New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
Topics: Brain; Central Nervous System Diseases; Dopamine; Female; Gene Expression; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1993 |
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.
Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Central Nervous System Diseases; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Serotonin; Syndrome | 1997 |